- No file added yet -

Data Supplement from Neuronal Pentraxin 2 Supports Clear Cell Renal Cell Carcinoma by Activating the AMPA-Selective Glutamate Receptor-4

figure

posted on 2023-03-30, 22:44 authored by Christina A. von Roemeling, Derek C. Radisky, Laura A. Marlow, Simon J. Cooper, Stefan K. Grebe, Panagiotis Z. Anastasiadis, Han W. Tun, John A. Copland

Supplementary Figure 2. (A) IF of non-permeabilized KIJ265T cells for NPTX2 expression. (B) Relative NPTX2 expression values of patient gene array data sorted into low versus high NPTX2 expression groups. (C) IF for NPTX2 (far left panel) and Fibronectin (far right panel) in A498 NT vs. sh1316 NPTX2 knockdown cells. 60x magnification of regions highlighted in 20x images are shown (central panels).

History

ARTICLE ABSTRACT

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer and has the highest propensity to manifest as metastatic disease. Recent characterizations of the genetic signature of ccRCC have revealed several factors correlated with tumor cell migration and invasion; however, the specific events driving malignancy are not well defined. Furthermore, there remains a lack of targeted therapies that result in long-term, sustainable response in patients with metastatic disease. We show here that neuronal pentraxin 2 (NPTX2) is overexpressed specifically in ccRCC primary tumors and metastases, and that it contributes to tumor cell viability and promotes cell migration through its interaction with the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor subunit GluR4. We propose NPTX2 as a novel molecular target for therapy for patients with ccRCC diagnosed with or at risk of developing metastatic disease. Cancer Res; 74(17); 4796–810. ©2014 AACR.